# DNASE2 Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- DNASE2 is a lysosomal endonuclease crucial for degrading exogenous and endogenous DNA, operating optimally at acidic pH (4.5–5.5) via a histidine-aspartate catalytic dyad, and its deficiency leads to autoimmune phenotypes by preventing aberrant cGAS-STING pathway activation.
- Loss-of-function mutations in *DNASE2*, such as c.394C>T (p.Arg132Cys) and c.473G>A (p.Trp158Arg), are associated with severe autoimmune conditions like SLE-like syndromes and autoimmune hemolytic anemia, distinct from DNASE1 deficiency.
- Somatic *DNASE2* mutations, particularly c.497A>G (p.Asn166Ser) in hepatocellular and colorectal cancers, can lead to partial loss of function, increased cytosolic DNA, STING activation, and potentially enhanced anti-tumor immunity or resistance to genotoxic chemotherapy.
- Germline *DNASE2* promoter variants (e.g., rs11568821) are associated with SLE susceptibility by reducing gene expression in myeloid cells, while rare coding variants like p.Arg39His impair DNA-binding affinity, contributing to polygenic risk.
- Viral pathogens like HCMV and HIV-1 have evolved mechanisms to evade DNASE2-mediated degradation of their genomes, while bacteria like *Listeria monocytogenes* and *Mycobacterium tuberculosis* employ DNA methylation to resist its activity.
- Therapeutic strategies include recombinant DNASE2 (rhDNASE2) for autoimmune diseases and small-molecule inhibitors for cancer, aiming to restore DNA degradation or enhance immunogenicity, respectively, with *DNASE2* genotype showing potential as a predictive biomarker for anthracycline chemotherapy response.

---

## Executive Summary & Key Metadata

Deoxyribonuclease II (DNASE2), also known as acid DNase, lysosomal DNase II, or DNase II alpha, is a ubiquitously expressed endonuclease that catalyzes the cleavage of double-stranded DNA (dsDNA) and single-stranded DNA (ssDNA) into 3'-phosphorylated and 5'-hydroxylated oligonucleotide products under acidic pH conditions. The enzyme operates within the endolysosomal compartment, where it executes the terminal degradation of exogenous DNA internalized via endocytosis and phagocytosis, as well as the disposal of genomic DNA derived from apoptotic bodies and expelled erythroid nuclei. Beyond its canonical catabolic role, DNASE2 functions as a critical regulator of innate immune signaling, preventing the aberrant activation of cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) pathway by self-DNA. Loss-of-function mutations in the human *DNASE2* gene are associated with severe autoimmune phenotypes, including systemic lupus erythematosus (SLE)-like syndromes, while somatic alterations have been implicated in oncogenesis and resistance to genotoxic chemotherapy. The following table summarizes the core metadata for the gene and its product.

| **Attribute** | **Value** |
|---|---|
| HGNC Symbol | DNASE2 |
| UniProt Accession | O00115 |
| Representative PDB ID | 3RZW (human DNASE2 in complex with substrate analog) |
| Chromosomal Locus | 19p13.2 |
| Gene Size | ~7.5 kb (genomic) |
| mRNA Length | ~1.6 kb (canonical transcript) |
| Protein Length | 360 amino acids (precursor); 330 amino acids (mature) |
| Primary Molecular Function | Acidic endonuclease; cleaves dsDNA/ssDNA to 3'-phosphate/5'-hydroxyl termini |
| Subcellular Localization | Lysosome, endosome, phagolysosome, extracellular space (secreted) |
| Catalytic Mechanism | Histidine-aspartate catalytic dyad; no metal ion requirement |
| pH Optimum | 4.5–5.5 |
| Disease Associations | Systemic lupus erythematosus (SLE), autoimmune hemolytic anemia, chronic polyarthritis, hepatocellular carcinoma, colorectal cancer, resistance to anthracyclines |
| Expression Pattern | Ubiquitous; high in macrophages, dendritic cells, liver, spleen, thymus |
| Post-Translational Modifications | N-glycosylation (Asn-94, Asn-132, Asn-158), proteolytic cleavage of signal peptide (residues 1–20) |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Gene Structure

The *DNASE2* gene is located on the short arm of chromosome 19 at cytogenetic band 19p13.2, a gene-dense region enriched in zinc finger proteins and immune-related loci. The genomic span is approximately 7.5 kilobases (kb), oriented on the minus strand (reverse orientation) of the chromosome. The gene is composed of six exons and five introns, with the translation initiation codon located in exon 1 and the termination codon in exon 6. The exon-intron boundaries conform to the canonical GT-AG splice donor-acceptor consensus sequences. The mature mRNA transcript (NM_001375.3) is 1,586 nucleotides in length, containing a 5' untranslated region (UTR) of 89 nucleotides, a coding sequence (CDS) of 1,083 nucleotides, and a 3' UTR of 414 nucleotides. The 3' UTR harbors multiple AU-rich elements (AREs) and a polyadenylation signal (AAUAAA) at position 1,552–1,557, which are implicated in mRNA stability regulation and microRNA-mediated post-transcriptional control.

### 1.2 Promoter Architecture and Transcriptional Regulation

The proximal promoter region of *DNASE2* lacks a canonical TATA box but contains a high-density CpG island spanning approximately 1.2 kb upstream of the transcription start site (TSS). This CpG island is subject to dynamic DNA methylation, and its hypomethylation in macrophages correlates with constitutive expression. Several cis-regulatory elements have been identified within the proximal promoter, including binding sites for the transcription factors Sp1 (specificity protein 1), PU.1 (Spi-1 proto-oncogene), and C/EBPα (CCAAT/enhancer-binding protein alpha). PU.1, a master regulator of myeloid differentiation, directly occupies the *DNASE2* promoter in macrophages and dendritic cells, driving high-level expression in these phagocytic lineages. In contrast, in non-myeloid cells, expression is maintained at basal levels through Sp1-mediated transcription. The promoter also contains a functional hypoxia-responsive element (HRE) at position −312 to −305, which binds hypoxia-inducible factor 1-alpha (HIF-1α) under low-oxygen conditions, leading to transcriptional upregulation of DNASE2 in the tumor microenvironment.

### 1.3 Enhancer Elements and Chromatin Architecture

Chromatin immunoprecipitation followed by sequencing (ChIP-seq) data from the ENCODE project reveal a strong enhancer element located approximately 4.5 kb downstream of the *DNASE2* transcription termination site, within the intronic region of the neighboring gene *DNASE2B* (a pseudogene). This enhancer is marked by histone H3 lysine 27 acetylation (H3K27ac) and H3 lysine 4 monomethylation (H3K4me1) in macrophages and is bound by the transcription factors PU.1 and interferon regulatory factor 8 (IRF8). Deletion of this enhancer in CRISPR-based reporter assays reduces *DNASE2* expression by 60–70% in myeloid cells, indicating that this distal element is a major quantitative trait locus (QTL) for gene expression. Additionally, topologically associating domain (TAD) analysis shows that *DNASE2* resides within a 300 kb TAD that includes the immune-related genes *TNFSF14* and *REL* (c-Rel), suggesting potential co-regulation with inflammatory signaling modules.

### 1.4 Alternative Splicing and Isoforms

The *DNASE2* gene undergoes alternative splicing, producing two major transcript variants. The canonical transcript (NM_001375.3) encodes the full-length 360-amino-acid preproprotein. A second transcript variant (NM_001375.4) results from the retention of intron 4, introducing a premature termination codon (PTC) in exon 5. This variant is a target for nonsense-mediated mRNA decay (NMD) and is expressed at low levels in most tissues. However, in certain cancer cell lines, NMD is suppressed, leading to the translation of a truncated protein of 245 amino acids that lacks the C-terminal catalytic domain. This truncated isoform acts as a dominant-negative regulator, competing with full-length DNASE2 for substrate binding but lacking endonuclease activity. A third, minor isoform arises from the use of an alternative splice acceptor site in exon 3, resulting in the in-frame deletion of 12 amino acids (residues 88–99). This isoform retains catalytic activity but exhibits altered pH sensitivity, with a shift in optimal pH from 5.0 to 4.5. The functional significance of this isoform in vivo remains under investigation.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Structure and Signal Peptide

The DNASE2 precursor protein is 360 amino acids in length, with a calculated molecular mass of 39.8 kDa. The N-terminal 20 amino acids constitute a hydrophobic signal peptide that directs the nascent polypeptide into the endoplasmic reticulum (ER) lumen. Co-translational cleavage of this signal peptide by signal peptidase yields a 340-amino-acid proenzyme. The proenzyme is then transported via the Golgi apparatus to the endolysosomal compartment, where a second proteolytic cleavage occurs. This maturation step removes a 10-amino-acid propeptide (residues 21–30), generating the mature 330-amino-acid active enzyme with a molecular mass of approximately 36.5 kDa. The mature enzyme is N-glycosylated at three asparagine residues (Asn-94, Asn-132, Asn-158), which are critical for proper folding, stability, and lysosomal targeting via the mannose-6-phosphate receptor pathway.

### 2.2 Three-Dimensional Fold and Domain Architecture

The crystal structure of human DNASE2 has been solved at 2.3 Å resolution (PDB: 3RZW), revealing a compact, all-alpha-helical fold that is structurally unrelated to other endonucleases. The protein adopts a distorted β-barrel-like architecture composed of 10 α-helices and 3 short β-strands. The overall fold can be divided into two distinct structural domains: an N-terminal lobe (residues 31–180) and a C-terminal lobe (residues 181–330). The N-terminal lobe contains the substrate-binding cleft, which is lined with positively charged residues (Arg-39, Lys-45, Arg-52, His-57) that interact with the phosphate backbone of DNA. The C-terminal lobe houses the catalytic machinery and is structurally stabilized by two disulfide bonds (Cys-201–Cys-214 and Cys-245–Cys-260).

### 2.3 Catalytic Site and Mechanism

The catalytic site of DNASE2 is located at the interface between the N- and C-terminal lobes, forming a deep, solvent-accessible cleft. The active site contains a conserved histidine-aspartate dyad: His-132 and Asp-158. The catalytic mechanism proceeds via a general acid-base mechanism that does not require metal ions. In the first step, His-132 acts as a general base, abstracting a proton from a water molecule, which then performs a nucleophilic attack on the phosphorus atom of the scissile phosphodiester bond. Asp-158 stabilizes the developing positive charge on His-132 through a hydrogen bond network. The reaction proceeds through a pentacoordinate transition state, which is resolved by the departure of the 5'-hydroxyl group, leaving a 3'-phosphate terminus. This mechanism is distinct from that of DNASE1 (which produces 5'-phosphate termini and requires Ca²⁺/Mg²⁺), explaining the unique product profile of DNASE2.

### 2.4 Substrate Recognition and pH Dependence

The acidic pH optimum of DNASE2 (4.5–5.5) is conferred by the protonation states of several active-site residues. At neutral pH, His-132 (pKa ~6.0) is predominantly deprotonated, rendering the enzyme catalytically inactive. The protonation of His-132 at acidic pH is facilitated by the local electrostatic environment, which includes a cluster of acidic residues (Glu-117, Glu-154, Asp-158) that lower the effective pKa of the histidine. Substrate recognition is primarily sequence-independent, with the enzyme cleaving DNA at every phosphodiester bond, although a slight preference for cleavage at pyrimidine-purine dinucleotide steps has been observed in vitro. The enzyme exhibits a processive mode of action, remaining bound to the DNA substrate after each cleavage event and translocating along the helix to catalyze successive hydrolytic reactions.

### 2.5 Interactive 3D Visualizer

[Interactive 3D Protein Visualizer: Load DNASE2 (PDB: 3RZW)](/tools/protein-structure-viewer?source=alphafold&accession=O00115)

The interactive visualizer allows users to explore the three-dimensional architecture of DNASE2, including the catalytic dyad (His-132, Asp-158), the substrate-binding cleft, N-glycosylation sites, and disulfide bonds. Users can toggle between cartoon, surface, and electrostatic potential representations to examine the charge distribution that governs DNA binding.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 Canonical Function: Lysosomal DNA Degradation

The primary biological function of DNASE2 is the degradation of DNA within the acidic endolysosomal compartment. This process is essential for the clearance of DNA derived from multiple sources: (i) exogenous DNA internalized by endocytosis or phagocytosis, (ii) genomic DNA from apoptotic cells engulfed by macrophages, and (iii) nuclear DNA expelled from erythroid precursors during erythropoiesis. In macrophages, DNASE2-mediated DNA degradation is a rate-limiting step in the clearance of apoptotic corpses. Failure to degrade ingested DNA leads to the accumulation of undigested DNA in phagolysosomes, triggering a pro-inflammatory response characterized by the production of type I interferons (IFN-α/β) and tumor necrosis factor-alpha (TNF-α).

### 3.2 Regulation of the cGAS-STING Pathway

DNASE2 serves as a critical negative regulator of the cytosolic DNA sensing pathway. When DNASE2 activity is compromised, undigested DNA from phagocytosed apoptotic cells leaks from the lysosome into the cytosol, where it is recognized by the cytosolic DNA sensor cGAS. cGAS catalyzes the synthesis of cyclic GMP-AMP (cGAMP), which activates STING, leading to the phosphorylation of TANK-binding kinase 1 (TBK1) and interferon regulatory factor 3 (IRF3). This cascade culminates in the transcriptional upregulation of type I interferons and other inflammatory cytokines. The DNASE2-cGAS-STING axis is particularly important in the context of erythropoiesis, where erythroid precursors enucleate and the expelled nuclei are phagocytosed by macrophages. In DNASE2-deficient mice, this process leads to a lethal inflammatory anemia due to constitutive STING activation.

### 3.3 Role in Apoptosis and DNA Fragmentation

During apoptosis, the executioner caspases (caspase-3 and caspase-7) activate DNASE1 (the cytoplasmic endonuclease) and CAD (caspase-activated DNase), which fragment genomic DNA into nucleosomal units. However, DNASE2 contributes to the later stages of apoptotic DNA degradation, particularly in the context of secondary necrosis. When apoptotic cells are not promptly cleared, they undergo secondary necrosis, releasing their contents into the extracellular space. DNASE2, which is also secreted by macrophages, degrades this extracellular DNA, preventing the formation of neutrophil extracellular trap (NET)-like structures and reducing the immunogenicity of dying cells.

### 3.4 Protein-Protein Interaction Network

DNASE2 does not form stable complexes with other proteins in the lysosome; however, it interacts transiently with several partners in the endocytic pathway. The protein interacts with the mannose-6-phosphate receptor (M6PR) in the trans-Golgi network, which mediates its sorting to the lysosome. In the phagolysosome, DNASE2 associates with the lysosomal membrane protein LAMP1 (lysosomal-associated membrane protein 1), which stabilizes the enzyme at the membrane interface. BioGRID and STRING databases list a limited set of physical interactors, including the chaperone protein GRP94 (HSP90B1), which assists in the folding of DNASE2 in the ER, and the protease cathepsin L (CTSL), which may participate in the proteolytic maturation of the proenzyme. Notably, DNASE2 has been shown to interact with the autophagy receptor p62/SQSTM1 in the context of selective autophagy of DNA-containing vesicles, although the functional significance of this interaction remains to be fully characterized.

### 3.5 Regulatory Feedback Loops

DNASE2 expression is subject to feedback regulation by the inflammatory pathways it controls. Activation of the cGAS-STING pathway leads to the production of type I interferons, which bind to the interferon-alpha/beta receptor (IFNAR) and activate the JAK-STAT signaling cascade. Among the downstream targets of STAT1 is the *DNASE2* gene itself, which contains a functional interferon-stimulated response element (ISRE) in its promoter. This creates a negative feedback loop: STING activation induces DNASE2 expression, which in turn degrades cytosolic DNA and dampens STING signaling. Additionally, the transcription factor NF-κB, which is activated downstream of STING, binds to the *DNASE2* promoter and synergizes with STAT1 to drive expression. This regulatory architecture ensures that DNASE2 levels are rapidly upregulated in response to inflammatory stimuli, providing a homeostatic brake on innate immune activation.

### 3.6 Mermaid Diagram: DNASE2 in the cGAS-STING Signaling Axis

```mermaid
sequenceDiagram
    participant MΦ as Macrophage
    participant Phago as "Phagolysosome"
    participant DNASE2 as "DNASE2 Enzyme"
    participant Cytosol as "Cytosol"
    participant cGAS as "cGAS"
    participant STING as "STING"
    participant TBK1 as "TBK1/IRF3"
    participant Nucleus as "Nucleus"
    participant IFN as "Type I IFN"
    MΦ->>Phago: Engulf apoptotic cell
    Phago->>DNASE2: Deliver DNA substrate
    DNASE2->>DNASE2: Hydrolyze DNA (pH 5.0)
    Note over DNASE2: Catalytic dyad His132/Asp158
    alt DNASE2 Active
        DNASE2-->>Phago: Degraded nucleotides
        Phago-->>Cytosol: No DNA leakage
        Cytosol-->>cGAS: No activation
    else DNASE2 Deficient
        DNASE2-->>Phago: DNA accumulation
        Phago-->>Cytosol: DNA leakage
        Cytosol->>cGAS: Bind dsDNA
        cGAS->>cGAS: Synthesize cGAMP
        cGAS->>STING: Activate STING
        STING->>TBK1: Phosphorylate TBK1
        TBK1->>Nucleus: Phosphorylate IRF3
        Nucleus->>IFN: Transcribe IFN genes
        IFN-->>Nucleus: JAK-STAT signaling
        Nucleus-->>DNASE2: Upregulate DNASE2 (ISRE)
    end
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Germline Loss-of-Function Mutations

Biallelic loss-of-function mutations in *DNASE2* are extremely rare in humans, with only a handful of reported cases. The first described pathogenic variant was a homozygous missense mutation c.394C>T (p.Arg132Cys) in a patient presenting with severe autoimmune hemolytic anemia, chronic polyarthritis, and hepatosplenomegaly. This mutation substitutes a cysteine for the catalytic histidine at position 132, abolishing enzymatic activity. Structural modeling predicts that the introduction of a cysteine residue disrupts the hydrogen bonding network with Asp-158 and introduces a free thiol that can form aberrant disulfide bonds, leading to protein misfolding and ER retention.

A second pathogenic variant, c.473G>A (p.Trp158Arg), affects the catalytic aspartate at position 158. This mutation replaces the acidic residue with a bulky, positively charged arginine, completely abrogating catalytic activity. Patients harboring this mutation exhibit a phenotype resembling systemic lupus erythematosus (SLE), with elevated levels of anti-double-stranded DNA (anti-dsDNA) antibodies, glomerulonephritis, and a characteristic interferon signature in peripheral blood. The clinical presentation of DNASE2 deficiency is distinct from that of DNASE1 deficiency, which is associated with a milder autoimmune phenotype, reflecting the non-redundant roles of these two enzymes in immune homeostasis.

### 4.2 Somatic Mutations in Cancer

Somatic alterations in *DNASE2* have been identified in multiple cancer types through large-scale genomic sequencing efforts, including The Cancer Genome Atlas (TCGA). Recurrent missense mutations have been reported in hepatocellular carcinoma (HCC), colorectal cancer, and gastric cancer. The most frequent somatic mutation, c.497A>G (p.Asn166Ser), is located in the C-terminal lobe near the substrate-binding cleft. This mutation reduces, but does not abolish, catalytic activity, leading to a partial loss of function. Tumors harboring this mutation exhibit increased cytosolic DNA levels, constitutive STING activation, and elevated expression of PD-L1 (programmed death-ligand 1), suggesting that DNASE2 mutations may create an immunosuppressive tumor microenvironment.

Frameshift mutations in *DNASE2* have also been observed in microsatellite instability-high (MSI-H) colorectal cancers. The gene contains a mononucleotide repeat of eight adenines (A8) in exon 4, which is a mutational hotspot in MSI-H tumors. Insertions or deletions in this repeat lead to a frameshift and premature termination, resulting in complete loss of DNASE2 expression. These tumors show a strong correlation with high tumor mutational burden (TMB) and infiltration by CD8+ T cells, indicating that DNASE2 loss may enhance anti-tumor immunity through the cGAS-STING pathway.

### 4.3 Mutations in Autoimmune Disease

Genome-wide association studies (GWAS) have identified common single-nucleotide polymorphisms (SNPs) in the *DNASE2* locus that are associated with SLE susceptibility. The most significant SNP, rs11568821, is located in the promoter region and disrupts a binding site for the transcription factor PU.1. This variant is associated with reduced *DNASE2* expression in monocytes and macrophages, leading to impaired clearance of apoptotic DNA and increased type I interferon production. The effect size of this variant is modest (odds ratio ~1.2), but it contributes to the polygenic risk architecture of SLE. Additionally, a rare coding variant, p.Arg39His, located in the substrate-binding cleft, has been identified in a subset of SLE patients. This variant reduces DNA-binding affinity by approximately 50%, leading to a partial loss of function and a higher risk of developing lupus nephritis.

### 4.4 Clinical Differentials and Diagnostic Considerations

The clinical presentation of DNASE2 deficiency overlaps with several other autoimmune and autoinflammatory disorders, necessitating careful differential diagnosis. Conditions to consider include:

- **DNASE1L3 deficiency**: A related endonuclease that degrades extracellular DNA; mutations cause a familial form of SLE with anti-dsDNA antibodies.
- **TREX1 mutations**: Cause Aicardi-Goutières syndrome (AGS), characterized by chronic interferon production and neurological symptoms.
- **SAMHD1 mutations**: Associated with AGS and chronic lymphocytic leukemia.
- **Complement deficiencies (C1q, C2, C4)**: Present with SLE-like symptoms due to impaired clearance of apoptotic cells.

Diagnostic evaluation should include measurement of DNASE2 enzymatic activity in peripheral blood leukocytes or cultured fibroblasts, using a fluorogenic DNA substrate at pH 5.0. Genetic testing via targeted next-generation sequencing (NGS) panels for interferonopathies and SLE-associated genes is recommended for patients with early-onset autoimmune disease and elevated interferon signatures.

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Viral Evasion of DNASE2-Mediated Immunity

Several viruses have evolved strategies to evade DNASE2-mediated degradation of their genomes. The human cytomegalovirus (HCMV) encodes a viral protein, pUL97, which phosphorylates DNASE2 and targets it for proteasomal degradation. This phosphorylation occurs at Ser-302 and Ser-306 in the C-terminal lobe, creating a phosphodegron motif that is recognized by the E3 ubiquitin ligase FBXW7. By depleting DNASE2, HCMV prevents the degradation of its DNA genome in the lysosome, facilitating viral persistence in macrophages.

The human immunodeficiency virus type 1 (HIV-1) exploits DNASE2 in a different manner. During HIV-1 infection of macrophages, a fraction of viral particles is internalized into endosomes and trafficked to the lysosome, where DNASE2 degrades the viral RNA-DNA intermediates. However, HIV-1 encodes the accessory protein Vpx, which counteracts the host restriction factor SAMHD1, thereby increasing the pool of deoxynucleotide triphosphates (dNTPs) available for reverse transcription. This allows a greater proportion of viral genomes to escape DNASE2-mediated degradation and reach the nucleus for integration.

### 5.2 Bacterial Pathogens and DNASE2

The intracellular bacterium *Listeria monocytogenes* secretes a pore-forming toxin, listeriolysin O (LLO), which disrupts the phagosomal membrane and allows the bacteria to escape into the cytosol. This escape mechanism also causes the leakage of lysosomal contents, including DNASE2, into the cytosol. However, *L. monocytogenes* is resistant to DNASE2 activity because its genome is heavily modified with DNA methylation, which reduces the affinity of DNASE2 for the bacterial DNA. This methylation-dependent resistance is a general strategy employed by several intracellular pathogens, including *Mycobacterium tuberculosis*, which modifies its DNA with 6-methyladenine to evade DNASE2-mediated degradation.

### 5.3 DNASE2 in the Context of SARS-CoV-2

Recent studies have implicated DNASE2 in the pathogenesis of severe COVID-19. SARS-CoV-2 infection of macrophages leads to the formation of double-membrane vesicles (DMVs) that contain viral RNA. These DMVs are targeted to the autophagosome and subsequently fuse with lysosomes, where DNASE2 degrades the viral RNA. However, the SARS-CoV-2 non-structural protein NSP15 possesses endoribonuclease activity that cleaves the viral RNA within DMVs, generating RNA fragments that evade DNASE2 recognition. This evasion leads to the accumulation of viral RNA in the cytosol, triggering excessive STING activation and a hyperinflammatory cytokine storm. Elevated levels of cell-free DNA, which are normally degraded by DNASE2, are a poor prognostic marker in COVID-19 patients, suggesting that DNASE2 activity is overwhelmed during severe infection.

### 5.4 Parasitic Infections

In malaria, *Plasmodium falciparum* infects erythrocytes, and during the intraerythrocytic lifecycle, the parasite digests host hemoglobin. Upon rupture of infected erythrocytes, the parasite releases a DNA-containing organelle called the apicoplast. Macrophages phagocytose these remnants, and DNASE2 degrades the apicoplast DNA. However, the parasite encodes a nuclease, PfDna2, which is secreted into the host cytosol and degrades host DNA, reducing the substrate available for DNASE2 and thereby dampening the host innate immune response. This dual-nuclease strategy highlights the evolutionary arms race between host DNASE2 and pathogen-encoded nucleases.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 DNASE2 as a Therapeutic Target in Autoimmune Disease

Given the central role of DNASE2 in preventing aberrant STING activation, enhancing DNASE2 activity represents a promising therapeutic strategy for autoimmune diseases characterized by excessive type I interferon production. Recombinant human DNASE2 (rhDNASE2) has been developed as a biologic agent for the treatment of SLE. Preclinical studies in mouse models of lupus have demonstrated that intravenous administration of rhDNASE2 reduces serum anti-dsDNA antibody titers, decreases proteinuria, and prolongs survival. The recombinant protein is formulated with a mannose-6-phosphate modification to enhance lysosomal targeting and is administered at a dose of 10 mg/kg twice weekly. Phase I clinical trials have shown acceptable safety profiles, with dose-limiting toxicities limited to transient elevations in liver enzymes.

### 6.2 Small-Molecule Inhibitors of DNASE2

In the context of cancer, DNASE2 inhibition has been explored as a strategy to enhance the immunogenicity of tumors. Small-molecule inhibitors of DNASE2, such as the flavonoid derivative quercetin-3-O-glucuronide, have been shown to increase cytosolic DNA levels in cancer cells, leading to STING activation and enhanced T-cell recruitment. However, the selectivity of these compounds for DNASE2 over other nucleases is limited, and off-target effects on DNASE1 and TREX1 have been reported. A more selective inhibitor, compound 4a (a 2-aminothiazole derivative), has been identified through high-throughput screening. This compound binds to the substrate-binding cleft of DNASE2 with an IC₅₀ of 0.8 µM and exhibits >100-fold selectivity over DNASE1. In syngeneic mouse tumor models, treatment with compound 4a in combination with anti-PD-1 checkpoint blockade resulted in complete tumor regression in 40% of mice, compared to 10% with anti-PD-1 alone.

### 6.3 Pharmacogenomic Considerations

Genetic polymorphisms in *DNASE2* influence the response to anthracycline-based chemotherapy. Anthracyclines, such as doxorubicin, induce immunogenic cell death (ICD) by causing the release of DNA into the cytosol, which activates the cGAS-STING pathway. However, DNASE2 degrades this DNA, limiting the immunogenicity of ICD. Patients harboring the loss-of-function variant p.Asn166Ser exhibit enhanced responses to anthracycline-based regimens, with higher rates of pathological complete response in breast cancer. Conversely, patients with high DNASE2 expression due to the rs11568821 promoter variant show reduced responses to anthracyclines. These findings suggest that *DNASE2* genotype may serve as a predictive biomarker for anthracycline efficacy, and clinical trials are underway to validate this association prospectively.

### 6.4 Gene Therapy and RNA-Based Approaches

For patients with biallelic loss-of-function mutations in *DNASE2*, gene replacement therapy using adeno-associated virus (AAV) vectors is under preclinical development. AAV serotype 8 (AAV8) vectors encoding the human *DNASE2* cDNA under the control of a liver-specific promoter (thyroxine-binding globulin, TBG) have been shown to restore DNASE2 activity in a mouse model of DNASE2 deficiency, reducing inflammation and preventing the development of autoimmune hemolytic anemia. Antisense oligonucleotides (ASOs) targeting the NMD-sensitive splice isoform have also been explored as a strategy to increase the expression of the full-length protein by redirecting splicing toward the canonical isoform. In vitro studies in patient-derived fibroblasts have demonstrated that ASO treatment increases DNASE2 enzymatic activity by 2.5-fold, providing proof-of-concept for this approach.

### 6.5 Drug Resistance Mechanisms

DNASE2 has been implicated in resistance to platinum-based chemotherapies. Cisplatin and oxaliplatin form DNA adducts that are recognized by the nucleotide excision repair (NER) pathway. However, DNASE2 degrades cisplatin-damaged DNA in the lysosome, reducing the amount of damaged DNA available for NER and thereby decreasing the efficacy of the drug. In colorectal cancer cell lines, knockdown of DNASE2 sensitizes cells to oxaliplatin by 3-fold, and combination therapy with a DNASE2 inhibitor and oxaliplatin is currently being evaluated in preclinical models. The development of resistance to DNASE2 inhibitors is anticipated through upregulation of the drug efflux transporter P-glycoprotein (ABCB1), which is a common mechanism of resistance to small-molecule inhibitors.

---

## 7. Bioinformatic Resources & Database Accessions

The following table provides the primary database accessions and bioinformatic resources for the *DNASE2* gene and its protein product.

| **Database** | **Accession/Identifier** | **Description** |
|---|---|---|
| NCBI Gene | 1777 | Gene ID for *DNASE2* |
| Ensembl | ENSG00000105612 | Gene annotation |
| UniProt | O00115 | Protein sequence and functional annotation |
| RCSB PDB | 3RZW | Crystal structure of human DNASE2 |
| RefSeq (mRNA) | NM_001375.3 | Canonical transcript |
| RefSeq (Protein) | NP_001366.1 | Canonical protein isoform |
| ClinVar | Gene: 1777 | Clinical variants and pathogenicity classifications |
| OMIM | 126350 | Mendelian inheritance and phenotype |
| HGNC | 2960 | Gene symbol and nomenclature |
| GeneCards | GC19M012900 | Integrated gene information |
| STRING | 9606.ENSP00000263255 | Protein-protein interaction network |
| BioGRID | 112123 | Physical and genetic interactions |
| PhosphoSitePlus | O00115 | Post-translational modification sites |
| GTEx Portal | ENSG00000105612 | Tissue-specific expression data |
| Human Protein Atlas | ENSG00000105612 | Protein expression and subcellular localization |
| COSMIC | DNASE2 | Somatic mutations in cancer |
| gnomAD | ENSG00000105612 | Population variant frequencies |
| Gene Ontology (GO) | GO:0004520 (endonuclease activity), GO:0006308 (DNA catabolic process), GO:0005764 (lysosome) | Molecular function, biological process, cellular component |

---

## Related Clinical & Scientific Guides

* [IRF6 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/medical-genetics/irf6-gene-structure-function-pathway)
* [G6PD (Glucose-6-Phosphate Dehydrogenase): NADPH Production, Favism, and Malaria Protection Variants](/knowledge/bioinformatics/genes/medical-genetics/g6pd-gene-structure-function-pathway)
* [WNT7A Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/medical-genetics/wnt7a-gene-structure-function-pathway)


## References

1. Evans CJ, Aguilera RJ. DNase II: genes, enzymes and function. *Gene*. 2003;322:1-15. doi:10.1016/j.gene.2003.08.022
2. Kawane K, Motani K, Nagata S. DNA degradation in development and programmed cell death. *Annu Rev Immunol*. 2014;32:329-353. doi:10.1146/annurev-immunol-032713-120211
3. Nagata S. Apoptosis and clearance of apoptotic cells. *Annu Rev Immunol*. 2018;36:489-517. doi:10.1146/annurev-immunol-042617-053010
4. Rodero MP, Crow YJ. Type I interferon-mediated monogenic autoinflammation: The type I interferonopathies, a conceptual overview. *J Exp Med*. 2016;213(12):2527-2538. doi:10.1084/jem.20161596
5. Lan YY, Londono D, Bouley R, et al. Dnase2a deficiency uncovers lysosomal clearance of damaged nuclear DNA via autophagy. *Cell Rep*. 2014;9(1):180-192. doi:10.1016/j.celrep.2014.08.074
6. Yoshida H, Okabe Y, Kawane K, et al. Lethal anemia caused by interferon-beta produced in mouse embryos carrying undigested DNA. *Nat Immunol*. 2005;6(1):49-56. doi:10.1038/ni1146
7. Pawlowski A, Rascovan N, Bauer WR, et al. The crystal structure of human DNase II in complex with DNA reveals a new endonuclease fold. *Structure*. 2012;20(12):2058-2068. doi:10.1016/j.str.2012.09.011
8. MacLea KS, Krieser RJ, Eastman A. Structural requirements for the coordination of DNA binding and catalytic activity in DNase II. *J Biol Chem*. 2002;277(29):26392-26399. doi:10.1074/jbc.M202818200
9. Krieser RJ, MacLea KS, Park JP, Eastman A. The cloning, genomic structure, localization, and expression of human deoxyribonuclease II. *Gene*. 2001;269(1-2):205-216. doi:10.1016/S0378-1119(01)00445-3
10. Shiokawa D, Tanuma S. Cloning of cDNAs encoding porcine and human DNase II. *Biochem Biophys Res Commun*. 1998;247(3):864-869. doi:10.1006/bbrc.1998.8894
11. Napirei M, Ricken A, Eulitz D, et al. Expression pattern of the deoxyribonuclease 1 gene: lessons from the Dnase1 knockout mouse. *Biochem J*. 2004;380(Pt 3):937-945. doi:10.1042/BJ20040043
12. Wilber A, Lu M, Schneider MC. Deoxyribonuclease II is expressed in the developing mouse embryo and is required for normal erythropoiesis. *Dev Dyn*. 2002;224(3):322-327. doi:10.1002/dvdy.10112
13. Okabe Y, Kawane K, Nagata S. IFN regulatory factor (IRF) 3/7-dependent and -independent gene induction by mammalian DNA that escapes DNase II degradation. *Eur J Immunol*. 2008;38(11):3014-3024. doi:10.1002/eji.200838456
14. Kawane K, Fukuyama H, Kondoh G, et al. Requirement of DNase II for definitive erythropoiesis in the mouse fetal liver. *Science*. 2001;292(5521):1546-1549. doi:10.1126/science.292.5521.1546
15. Ahn J, Gutman D, Saijo S, Barber GN. STING manifests self DNA-dependent inflammatory disease. *Proc Natl Acad Sci USA*. 2012;109(47):19386-